Richard Law
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
50
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Initiates: Neutral | $45 | $25.39 | +77.24% | 1 | Sep 30, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $25 → $31 | $22.84 | +35.73% | 2 | Sep 12, 2024 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $30 | $13.50 | +122.22% | 5 | Apr 2, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $24 | $11.86 | +102.36% | 4 | Apr 2, 2024 | |
| RCKT Rocket Pharmaceuticals | Initiates: Neutral | $39 | $16.82 | +131.87% | 1 | Apr 2, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Neutral | $62 | $46.40 | +33.62% | 1 | Apr 2, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $8.84 | +24.43% | 4 | Aug 11, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $31 | $6.05 | +412.40% | 2 | Aug 11, 2023 | |
| BEAM Beam Therapeutics | Maintains: Neutral | $46 → $47 | $24.36 | +92.94% | 3 | Aug 9, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $62 → $63 | $50.59 | +24.53% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $47.07 | -21.39% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $15.14 | +401.98% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.88 | +386.11% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $26.80 | +127.61% | 4 | May 8, 2023 |
Celldex Therapeutics
Sep 30, 2024
Initiates: Neutral
Price Target: $45
Current: $25.39
Upside: +77.24%
Viridian Therapeutics
Sep 12, 2024
Maintains: Buy
Price Target: $25 → $31
Current: $22.84
Upside: +35.73%
Mineralys Therapeutics
Apr 2, 2024
Initiates: Buy
Price Target: $30
Current: $13.50
Upside: +122.22%
Olema Pharmaceuticals
Apr 2, 2024
Initiates: Buy
Price Target: $24
Current: $11.86
Upside: +102.36%
Rocket Pharmaceuticals
Apr 2, 2024
Initiates: Neutral
Price Target: $39
Current: $16.82
Upside: +131.87%
MoonLake Immunotherapeutics
Apr 2, 2024
Initiates: Neutral
Price Target: $62
Current: $46.40
Upside: +33.62%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $8.84
Upside: +24.43%
Verve Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $6.05
Upside: +412.40%
Beam Therapeutics
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $24.36
Upside: +92.94%
CRISPR Therapeutics AG
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $50.59
Upside: +24.53%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $47.07
Upside: -21.39%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $15.14
Upside: +401.98%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.88
Upside: +386.11%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $26.80
Upside: +127.61%